AbbVie Inc. ABBV, +1.94% on Friday reported fourth-quarter sales that topped analysts’ estimates, even as it faces low-cost competition for its top-selling drug, Humira. The drugmaker reported fourth-quarter net income of $822 million, or 46 cents per share, down sharply from $2.473 billion, or $1.38 per share, in the year-earlier period. Adjusted earnings per share of $2.79, which included an unfavorable impact of 15 cents a share related to acquired in-process research and development expenses, matched th ...

文章核心观点 - 公司2023年全年业绩表现出色,非Humira业务增长强劲,但受Humira专利到期影响整体收入下降[1][2] - 公司通过收购ImmunoGen和Cerevel Therapeutics进一步丰富了肿瘤和神经科学领域的管线[17][18] - 公司预计2024年业绩将受到收购事项的一定影响,但长期增长前景仍然良好,预计未来几年保持高个位数的复合年增长率[27][28] 业务板块总结 免疫学业务 - 免疫学业务收入下降9.6%,主要受Humira专利到期影响,但Skyrizi和Rinvoq收入大幅增长[3] - Humira全球收入下降32.2%,其中美国市场下降34.7%,国际市场下降14.3%[38] - Skyrizi全球收入增长50.3%,Rinvoq全球收入增长57.4%[38] 肿瘤业务 - 肿瘤业务收入下降10.1%,主要受Imbruvica收入下降21.3%的影响,Venclexta收入增长13.9%[38] 神经科学业务 - 神经科学业务收入增长18.2%,主要得益于Botox治疗剂、Vraylar和Ubrelvy等产品的强劲表现[9] - Botox治疗剂收入增长10.0%,Vraylar收入增长35.4%,Ubrelvy收入增长19.9%[38] 美学业务 - 美学业务收入下降0.8%,Botox美容和Juvederm收入分别增长2.6%和下降3.6%[38] 其他信息 - 公司2023年第四季度调整后每股收益为2.79美元,全年调整后每股收益为11.11美元[15][40] - 公司预计2024年调整后每股收益将为11.05-11.25美元,其中包括收购事项的0.32美元摊薄影响[27] - 公司预计未来几年保持高个位数的复合年增长率,并大幅提高了Skyrizi和Rinvoq以及Ubrelvy和Qulipta的长期销售预期[28][29][30]

生物技术行业发展趋势 - 生物技术行业预计在2023年至2030年间复合年增长率接近13%[1] 人工智能在生物技术领域的应用 - 人工智能在生物技术领域有重要应用[2] - CRISPR基因编辑技术不断发展，包括商业层面的新应用[2] AbbVie公司的销售情况 - AbbVie公司的销售主要受其明星药物Humira的影响[4] - 公司正在积极用新药替代Humira的销售下滑[4]

-- New report incorporates in-depth interviews, industry research and social listening to understand the role of individuality in the world of aesthetics ---- Report underpins ongoing commitment to aesthetics accessibility and inclusivity to achieve desired patient outcomes --IRVINE, Calif., Jan. 31, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie (NYSE: ABBV) company and a global leader in medical aesthetics treatments, released the "Decoding the Future of Aesthetic Individuality" report, which ...

盈利预期 - AbbVie (ABBV) 预计每股季度盈利为2.79美元，同比下降22.5%[1] - 过去30天，盈利每股预期下调0.7%[2] 营收预期 - 预计营收为140.6亿美元，同比下降7%[1] 分析师预测 - 分析师的盈利预期变化对股票价格表现有重要影响[3] - 探索分析师对特定关键指标的预测可以提供有价值的见解[4]

We see daily analyst upgrades and downgrades, coming with price targets. They can be helpful tools for investors, providing a more structured plan and helping to inject positivity surrounding future performance.Of course, stocks don’t straightforwardly reach price targets, as unforeseen circumstances can always influence performance. Overall, the positive shift in sentiment can be seen as a primary takeaway from these upgrades.  Recently, three stocks – AbbVie (ABBV) , Hershey (HSY) , and Dollar Tree (DLTR) ...

The most recent trading session ended with AbbVie (ABBV) standing at $163.91, reflecting a -0.3% shift from the previouse trading day's closing. The stock trailed the S&P 500, which registered a daily gain of 0.76%. On the other hand, the Dow registered a gain of 0.59%, and the technology-centric Nasdaq increased by 1.12%.Shares of the drugmaker witnessed a gain of 6.09% over the previous month, beating the performance of the Medical sector with its gain of 1.57% and the S&P 500's gain of 2.5%.Investors wil ...

There's one constant you can always rely on. Regardless of what's happening to the overall economy, people keep racking up higher healthcare bills as they get older. And nowadays there are more folks racking up those bills.From 1920 through 2020, America's over-65 population grew nearly five times faster than the total population.Aging baby boomers pushed older population growth into high gear during the decade between 2010 and 2020. In the latest U.S. Census, the number of over-65 adults rose 38% to 56 mil ...

Jun/iStock via Getty Images Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) is a clinical-stage biotechnology company focusing on developing treatments for immune-mediated inflammatory diseases. Its leading drug candidate is Reproxalap for dry eye and allergic conjunctivitis. It is a RASP modulator that reduces the generation of pro-inflammatory cytokines, a critical step for treating various ocular conditions. ALDX will resubmit in the first semester of 2024 the FDA approval request for this drug applied to d ...

医疗保健行业表现 - 2023年医疗保健行业表现一般，未能像科技行业那样取得飞速增长，但仍有投资价值[3] - 医疗保健行业具有防御性特征，即使在经济状况不佳时也能保持稳定的盈利和现金流[4] AbbVie Inc. (ABBV) - ABBV是值得投资的医疗保健公司，提供稳定且不断增长的股息收入[5] - ABBV面临Humira专利悬崖的挑战，但通过推出新药物如Skyrizi和Rinvoq，成功稳定了公司的收入增长[14] - ABBV在2023年第三季度业绩表现良好，提高了全年调整后的每股收益指导，展望2024年也乐观[17] - ABBV持续增加股息，展现了稳健的财务表现，尽管股价略显高估，但仍是一家具有吸引力的医疗保健公司[18][20][21] Merck & Co., Inc. (MRK) - MRK是值得投资的医疗保健公司，提供稳定且不断增长的股息收入[5] - MRK的主要药物Keytruda和Gardasil取得了显著增长，推动了销售额的提升[23][24] - MRK在2023财年的收益出现下滑，主要是因为收购Prometheus而产生的一次性费用，但未来趋势仍然向好[27] - MRK也面临Keytruda专利保护到2028年结束的挑战，需要不断推出新产品以取代[29][30] - MRK的股息增长虽然不及ABBV，但仍在稳步增长，公司的盈利和自由现金流也呈现良好趋势[31][34][36]